HC Wainwright & Co. Reiterates Buy on CervoMed, Maintains $25 Price Target

Benzinga · 2d ago
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates CervoMed (NASDAQ:CRVO) with a Buy and maintains $25 price target.